Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KCNK3 | O14649 | 5/20 | 0.52 |
| ▸ | KCNK9 | Q9NPC2 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MLNR | O43193 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4322726 | 0.88 | CA1 (0.58) | KMT2AMEN1ALDH1A1MAPK1LMNA | |
| SCHEMBL4338244 | 0.84 | KMT2A (0.57) | KMT2AMEN1KCNK3KCNK9MAPK1 | |
| SCHEMBL4335312 | 0.84 | KMT2A (0.57) | KMT2AMEN1KCNK3KCNK9MAPK1 | |
| SCHEMBL27886857 | 0.83 | MEN1 (0.63) | KMT2AMEN1ALDH1A1KCNK3KCNK9 | |
| SCHEMBL2703311 | 0.79 | P2RX1 (0.63) | KMT2AMEN1ALDH1A1KCNK3KCNK9 | |
| SCHEMBL4328024 | 0.79 | PTGS2 (0.54) | KMT2AALDH1A1LMNAMAPTCYP3A4 | |
| SCHEMBL4337324 | 0.79 | HSD17B10 (0.52) | KMT2AMEN1ALDH1A1MAPK1LMNA | |
| SCHEMBL10192623 | 0.78 | KMT2A (0.68) | KMT2AMEN1ALDH1A1KCNK3KCNK9 | |
| SCHEMBL11590109 | 0.78 | KCNK3 (0.68) | KMT2AALDH1A1KCNK3KCNK9MAPK1 | |
| SCHEMBL2699624 | 0.78 | KCNK3 (0.59) | KMT2AMEN1KCNK3KCNK9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709155-B1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CHESTERFORD ENTPR LTD (KY) | 2013-10-02 | — | — | EP | disclosed |
| US-7585997-B2 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CHESTERFORD ENTERPRISES LIMITED (KY) | 2009-09-08 | — | — | US | disclosed |
| EP-1709155-A4 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | KASHFI KHOSROW (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1709155-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | Kashfi, Khosrow (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050182134-A1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CONVERSANT INTELLECTUAL PROPERTY MANAGEMENT INC. (CA) | 2005-08-18 | — | — | US | disclosed |
| WO-2005065361-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | KASHFI KHOSROW (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182134-A1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | PYGL, TP53, MKI67 | KMT2A 4350/4885MEN1 1240/4885ALDH1A1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.